# Vyndaqel Capsules Special Investigation (ATTR-CM)

> **NCT04108091** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1214 (actual)

## Conditions studied

- Transthyretin (TTR) Amyloid Cardiomyopathy

## Interventions

- **DRUG:** Treatment for TTR amyloidosis
- **DRUG:** Treatment for TTR amyloidosis

## Key facts

- **NCT ID:** NCT04108091
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-03
- **Primary completion:** 2025-03-27
- **Final completion:** 2025-03-27
- **Target enrollment:** 1214 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108091, "Vyndaqel Capsules Special Investigation (ATTR-CM)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04108091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*